FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Gestational Age (SGA), or Noonan Syndrome (NS)1 Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to...